BIOTECH VANA SL

Their core work

Biotech VANA is a Valencia-based biotech SME that applies omics technologies — genomics, proteomics, metabolomics — to translational medical research, bridging laboratory data to clinical diagnostics and therapeutic applications. Their participation in OPATHY points to expertise in fungal pathogen identification using multi-omics pipelines, while MAST4HEALTH reveals a second track in nutraceutical clinical research, specifically evaluating natural compounds against metabolic liver disease. As an industrial SME inside MSCA training networks, they likely provide real-world biotech context and analytical services that complement the academic partners in the consortium. Their work is applied and translational: turning biological data into diagnostics or evidence-based treatment protocols.

What they specialise in

How they've shifted over time

Both projects started within one year of each other (2015 and 2016) and ran concurrently through to 2019–2020, so there is no meaningful temporal shift to analyze — this is a snapshot of a single phase of activity, not a multi-phase trajectory. What the pairing does reveal is a deliberate dual focus: one track in infectious disease diagnostics (fungal pathogens via omics), and a parallel track in chronic metabolic disease (liver disease via natural compounds). Whether these two tracks represent a broadening strategy or simply two separate client relationships within the company cannot be determined from this data alone.

With only two projects from the same narrow window (2015–2016 starts), there is insufficient data to identify a trend; any future collaboration should probe directly whether their current focus is diagnostics, metabolic disease, or both.

How they like to work

Biotech VANA has participated exclusively as a consortium partner, never as coordinator, across both projects. Both were large, internationally distributed consortia — MSCA-ITN-ETN and MSCA-RISE schemes that by design span multiple countries and institutions — which means they are accustomed to operating as one specialist node among many. Their role in these networks was likely to provide industrial biotech capacity: hosting researcher secondments, running analytical workflows, or supplying applied validation work alongside academic partners.

Biotech VANA has built connections with 23 unique partners across 12 countries through just two projects — a notably broad network for a small SME, reflecting the international character of MSCA schemes. No geographic concentration is evident; their partner countries likely include Southern and Central Europe given the consortium profiles of health-focused MSCA projects.

What sets them apart

Biotech VANA occupies an unusual niche as an SME that bridges two distinct health domains — infectious disease diagnostics and metabolic liver disease — through the common lens of omics and biomarker science. For consortium builders, they offer the industrial credibility and applied analytical capacity that MSCA and other EU funding schemes require from private-sector partners. A Spanish biotech SME with this dual clinical-research profile is rare; most Valencia-based biotechs focus on a single therapeutic area.

Highlights from their portfolio

• OPATHY
  The largest-funded project (EUR 247,873) and the more technically distinctive one — applying the full omics pipeline to fungal pathogen diagnostics is a narrow, high-value specialty with direct clinical relevance to immunocompromised patient care.
• MAST4HEALTH
  An unusual combination of traditional botanical medicine (mastiha resin, used in Greek herbal traditions) and modern hepatology, run as a structured clinical trial — demonstrates capacity for rigorous evidence generation around natural compounds.